Novo Nordisk to offer Ozempic at $499 per month to eligible US customers – One America News Network

0
144

By Reuters
August 18, 2025 – 7:48 AM PDT

Pens for the diabetes drug Ozempic. REUTERS/Tom Little/File Photo

(Reuters) – Novo Nordisk (NOVOb.CO) said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 diabetes patients in the United States.

Earlier this month, it said it expects continued competition from copycat versions of its blockbuster obesity drug Wegovy this year and rising pressure from main U.S. rival, Eli Lilly (LLY.N).

Novo said the new offer was part of its ongoing efforts to explore new collaborations and approaches towards improving access to authentic semaglutide medicines.

Advertisement

The offer will roll out across multiple platforms. Ozempic will be available through its NovoCare pharmacy program – launched earlier this year to sell Wegovy outside of insurance – for…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here